Here, we report on vaccine efficacy against controlled human malaria infection delivered by mosquito bites. falciparum blood-stage antigens by chimpanzee adenovirus 63 (ChAd63) followed by the attenuated orthopoxvirus MVA is safe and immunogenic in healthy adults. We have shown that prime-boost delivery of P. The induction of cellular immunity, in conjunction with antibodies, may be essential for vaccines to protect against blood-stage infection with the human malaria parasite Plasmodium falciparum. Sheehy, Susanne H Duncan, Christopher J A Elias, Sean C Choudhary, Prateek Biswas, Sumi Halstead, Fenella D Collins, Katharine A Edwards, Nick J Douglas, Alexander D Anagnostou, Nicholas A Ewer, Katie J Havelock, Tom Mahungu, Tabitha Bliss, Carly M Miura, Kazutoyo Poulton, Ian D Lillie, Patrick J Antrobus, Richard D Berrie, Eleanor Moyle, Sarah Gantlett, Katherine Colloca, Stefano Cortese, Riccardo Long, Carole A Sinden, Robert E Gilbert, Sarah C Lawrie, Alison M Doherty, Tom Faust, Saul N Nicosia, Alfredo Hill, Adrian V S Draper, Simon J
SCT DEVICE UPDATER V2.9.8.95 REGISTRATION
Trial Registration NCT00308061 PMID:18213374ĬhAd63-MVA-vectored blood-stage malaria vaccines targeting MSP 1 and AMA 1: assessment of efficacy against mosquito bite challenge in humans. This malaria vaccine is being evaluated in Phase 1 and 2 trials in children at this site. 1/AS02A vaccine had a good safety profile, was well-tolerated, and was highly immunogenic in malaria-exposed adults. Anti- AMA- 1 antibodies increased significantly in both malaria vaccine groups, peaking at nearly 5-fold and more than 6-fold higher than baseline in the half-dose and full-dose groups, respectively. Transient local pain and swelling were common and more frequent in both malaria vaccine dosage groups than in the comparator group. falciparum growth inhibition assays were performed on sera collected at pre- and post-vaccination time points. Titers of anti- AMA- 1 antibodies were measured by ELISA and P. Serious adverse events were assessed throughout the study. Solicited symptoms were assessed for 7 d and unsolicited symptoms for 30 d after each vaccination. 1 50 µg/AS02A 0.5 mL) or rabies vaccine given in 3 doses at 0, 1 and 2 mo, and were followed for 1 y.
SCT DEVICE UPDATER V2.9.8.95 FULL
Sixty healthy, malaria-experienced adults aged 18–55 y were recruited into 2 cohorts and randomized to receive either a half dose or full dose of the malaria vaccine (FMP2. The comparator vaccine was a cell-culture rabies virus vaccine (RabAvert). 1) based on apical membrane antigen- 1 ( AMA- 1) from the 3D7 clone of P. Methodology/Principal Findings A phase 1 double blind randomized controlled dose escalation trial was conducted in Bandiagara, Mali, West Africa, a rural town with intense seasonal transmission of Plasmodium falciparum malaria. 1/AS02A in adults exposed to seasonal malaria. Plowe, Christopher V.īackground The objective was to evaluate the safety, reactogenicity and immunogenicity of the AMA- 1-based blood-stage malaria vaccine FMP2. Leach, Amanda Owusu, Alex Dubois, Marie-Claude Cohen, Joe Nixon, Jason N. Dutta, Sheetij Soisson, Lorraine Diggs, Carter L. Ann Angov, Evelina Bergmann-Leitner, Elke S. Baby, Mounirou Sissoko, Mady Diarra, Issa Niangaly, Amadou Dolo, Amagana Daou, Modibo Diawara, Sory I. Traore, Karim Dicko, Alassane Sagara, Issaka Sissoko, Mahamadou S. For Permissions, please email: and Immunogenicity of an AMA- 1 Malaria Vaccine in Malian Adults: Results of a Phase 1 Randomized Controlled Trial The observed association between α-thalassaemia and malaria antibody responses may reflect longer-term differences in antigen exposure or differences in antibody acquisition upon exposure in this low endemic setting. Being heterozygous or homozygous for α-thalassaemia was associated with an increased prevalence of antibodies to AMA- 1 and MSP- 1 (OR: 2.04, 95% CI: 1.16-3.60, p = 0.013) after adjustment for age and reported bednet use. During the 1 year follow-up, four incidents of malaria cases were detected without an evident association with α-thalassaemia. 1% (16 of 394) and 30.7% (121 of 394) were homozygous and heterozygous, respectively. Out of 394 children genotyped for α-thalassaemia trait, 4. α-Thalassaemia trait is associated with antibody prevalence against malaria antigens AMA- 1 and MSP- 1.ĭaou, Modibo Kituma, Elimsaada Kavishe, Reginald Chilongola, Jaffu Mosha, Frank van der Ven, André Kouriba, Bourema Bousema, Teun Sauerwein, Robert Doumbo, OgobaroĪ longitudinal study was conducted in a low endemic area in northern Tanzania to examine the influence of the α-thalassaemia trait on malaria incidence and antibody responses to malaria apical membrane antigen- 1 ( AMA- 1) and merozoite surface protein 1-19 (MSP-119).
0 kommentar(er)
